BigHat Biosciences

BigHat Biosciences is a biotech startup that operates in the field of antibody therapies. The company uses machine learning and synthetic biology to design safer and more effective treatments for patients suffering from a variety of challenging diseases. Their primary focus is on diseases that are difficult to treat, such as certain types of infections and cancers.

BigHat Biosciences' business model revolves around their proprietary Milliner platform. This platform combines a synthetic biology-based wet lab with advanced machine learning technologies to create a comprehensive antibody discovery and engineering platform. The Milliner platform allows for the synthesis, purification, and full characterization of hundreds of recombinant antibodies in a single weekly workcell. This high-speed process results in the development of better antibodies at a faster rate.

The company serves a broad range of clients, including healthcare providers and patients. They operate in the biotech market, specifically in the area of antibody therapies. The company generates revenue by developing and selling their antibody therapies.

BigHat Biosciences is based outside of San Francisco and has raised over $100 million in funding from top investors. Despite being a high-performance company, BigHat Biosciences also emphasizes work-life balance and a family-friendly culture.

Keywords: Biotech, Antibody Therapies, Machine Learning, Synthetic Biology, Milliner Platform, High-Speed Characterization, Recombinant Antibodies, Intractable Diseases, Work-Life Balance, Series B Funding.